NASDAQ: IKNA - Ikena Oncology, Inc.

Lønnsomhet i seks måneder: -5.52%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Ikena Oncology, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Ikena Oncology, Inc.

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas.

flere detaljer
Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2021-03-26
ISIN US45175G1085
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://ikenaoncology.com
Цена ао 1.39
Prisendring per dag: -1.91% (1.57)
Prisendring per uke: -0.6452% (1.55)
Prisendring per måned: -8.88% (1.69)
Prisendring over 3 måneder: -10.98% (1.73)
Prisendring over seks måneder: -5.52% (1.63)
Prisendring per år: -21.83% (1.97)
Prisendring over 3 år: -89.1% (14.13)
Prisendring over 5 år: 0% (1.54)
Prisendring over 10 år: 0% (1.54)
Prisendring siden begynnelsen av året: -10.47% (1.72)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 9.52 1
P/BV 0.5138 10
P/E 0 0
EV/EBITDA 0.2948 10
Total: 5.13

Effektivitet

Navn Betydning Karakter
ROA, % -35.49 0
ROE, % -40.16 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.1443 10
Total: 8.4

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -33.62 0
Lønnsomhet Ebitda, % 308.77 10
Lønnsomhet EPS, % 36.11 5
Total: 5
Flere detaljer

Institusjoner Volum Dele, %
Orbimed Advisors LLC. 9907945 20.53
Atlas Venture Life Science Advisors, LLC 5018178 10.4
BVF Inc. 4769164 9.88
FMR, LLC 4184293 8.67
Omega Fund Management, Llc 2249123 4.66
Blue Owl Capital Holdings LP 1953616 4.05
Blackrock Inc. 1858156 3.85
Vanguard Group Inc 1524848 3.16
Verition Fund Management, LLC 1322397 2.74
Artal Group S.A. 999513 2.07

ETF Dele, % Lønnsomhet for året, % Utbytte, %
iShares Micro-Cap ETF 0.0129 17.09 1.54048



Veileder Stillingstittel Betaling Fødselsår
Dr. Mark Manfredi Ph.D. President, CEO & Director 810.69k 1971 (54 år)
Dr. Jotin Marango M.D., Ph.D. CFO & Head of Corporate Development 577.12k 1979 (46 år)
Mr. Bob Lally Senior Vice President of Finance & Operations N/A
Mr. Jeffrey Ecsedy Ph.D. Chief Development Officer N/A 1970 (55 år)
Mr. David Damphousse M.S. Senior Vice President of Clinical Development Operations N/A
Mr. Valdas Jurkauskas Ph.D. Senior Vice President of Technical Operations N/A
Dr. Caroline Germa M.D., Ph.D. Chief Medical Officer N/A 1972 (53 år)
Ms. Rebecca Cohen Vice President of Investor Relations, Corporate Strategy & Communication

Adresse: United States, Boston. MA, 645 Summer Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://ikenaoncology.com